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irradiated with 2x5 Gy than we surgically removed this lesion 
11 days after RT. Diffusion Weighted (DW) and Dynamic 
Contrast Enhancement (DCE) -MRI was performed every 2 
days during 11 days between RT and surgery. Control group 
(i.e. non irradiated tumor bearing mice) was processed in 
parallel for MRI and surgery. We developed a homemade 
'portacath (PAC)' specifically dedicated for mice and for 
repetitive i.v. gadolinium contrast agent injection. For each 
tumors we acquired 5 slices of 0.6 mm thickness and 0.3mm 
gap between each slices with an 'in plane voxel resolution' of 
0.34 mm². We kept the same slices position for DCE and DW-
MRI. For DW-MRI, we performed FSEMS (Fast Spin Echo 
MultiSlice) sequences, with 10 different B-value (form 20 to 
1000) and B0, in the 3 main directions. With this amount of 
B-value, we performed IVIM (IntraVoxel Incoherent Motion) 
analysis, in the aim to obtain information on intravascular 
diffusion and subsequently tumor vessels perfusion. For DCE-
MRI, we used FSEMS sequence for keeping the same 5 slices 
as with DW-MRI. After the T1 mapping, we performed DCE 
acquisition with a temporal resolution of 5.6 sec. After 10 
repetitions, we injected 100 µl of gadopentetate 
dimeglumine (0.1 mmol/kg) in 5 sec. via the PAC and 
recorded the 190 following repetitions during 14 min. for the 
contrast enhancement and wash out. For both images, we 
performed analysis on the entire tumor volume and we 
obtained the mean tumor signal. 
Results: We obtained very promising preliminary results 
showing good uniformity in the ADC (Attenuation Diffusion 
Coefficient). We succeeded to follow mice with imaging 
during the 11 days without major troubles. We observed less 
variability of the ADC signal during the 11 days in the 
irradiated tumors compared to the control. The signal to 
noise ratio was relatively poor for the diffusion sequence and 
the perfusion fraction. 
Conclusions: For the first time, we demonstrate the 
feasibility of repetitive MRI functional imaging in a mice 
model of NeoRT. These results open perspectives for studying 
modifications of the tumor microenvironment induced by 
neoadjuvant RT. The techniques need to be improved and 
correlated to the tumor dissemination in function of the RT 
schedule and timing of surgery. 
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Purpose/Objective: Interim analysis of a clinical trial to test 
the tolerability and efficacy of the visual feedback of 
dynamic measurement of lung cancer patients’ body surfaces 
in aiding motion management during radiotherapy 
Materials and Methods: Christie Medical Physics and 
Engineering have previously developed a wide field, real-time 
optical surface measurement device for use during 
radiotherapy [1]. A pilot study, using the device to provide 
visual feedback to patients with the aim of helping them self-
manage their intra-fraction motion was conducted in healthy 
volunteers and demonstrated improved control and reduced 
variability [2].  
However, before the clinical potential of the device can be 
assessed, it is vital to know: (i) if the device can be tolerated 
and understood by often elderly patients who commonly 
present with severe co-morbidities, and (ii) if external 
control of intra-fraction motion correlates to reduced 
internal anatomical variability. We present an interim 
analysis of the first patients from a clinical study designed to 
answer these questions (Ethics committee ref. 14/NW/0037). 
Each lung cancer patient recruited to the study is asked to 
undertake 4 sessions in which they use the visual feedback 
device. The device uses three different visualization schemes 
to show the deviation of the patients’ live body surfaces from 
their ideal treatment position. Surface measurements 
captured whilst the patient uses each scheme are compared 
to data acquired during unaided free-breathing immediately 
beforehand. Additionally 4D CBCT scans are acquired during 
free breathing and whilst using the ‘traffic light’ visualization 
scheme (Figure 1). 
 
 
Figure 1 – Showing (a-c) the method of operation of the 
surface measurement device and (d) the clinical trial 
protocol. The sensor projects a fringe pattern onto the 
patient (a), analysis of the modulation of which yields the 
body topology (b). Deviation of the surface from its ideal is 
displayed as a colour-wash over the live surface (c) or in 
more abstract format (d). 
Results: Tolerance, measured as the percentage of patients 
completing all training and imaging sessions, is currently at 
100%. Initial analysis shows patients are able to reduce their 
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respiratory motion whilst using the device, but that 
interpretation of the visualization schemes can be quite 
literal. This can lead, for example, to ‘target driven’ 
pulsatile breath holding rather than quiescent, smooth 
motion patterns.  
Conclusions: This interim analysis shows that the visual 
feedback device is well tolerated in lung cancer patients. The 
optical surface measurement technology delivers fast and 
accurate skin surface measurements. However, great care 
must be taken with the psychology of visual feedback schema 
in order to encourage predictable patient response. 
1. G.J. Price et al., doi: 10.1088/0031-9155/57/2/415 
(2012). 
2. J.M. Parkhurst et al., doi: 10.1016/j.ijrobp.2013.08.048 
(2013).  
   
EP-1528   
Should we extend the daily image guidance scans for 
toxicity studies? A VoxTox experience 
M. Romanchikova1, S.J. Thomas1, A. Bates2, J. Scaife3, K. 
Harrison4, R. Jena3, N.G. Burnet3 
1Cambridge University Hospitals, Medical Physics and Clinical 
Engineering, Cambridge, United Kingdom  
2Cambridge University Hospitals, Oncology, Cambridge, 
United Kingdom  
3University of Cambridge, Addenbrooke's Hospital, 
Department of Oncology  
4Cavendish Laboratories University of Cambridge, Physics, 
Cambridge, United Kingdom  
 
Purpose/Objective: Rectal toxicity is one the major 
constraints in prostate cancer radiotherapy (RT). It has been 
shown that various manifestations of rectal toxicity strongly 
correlate with the dose distribution on the surface of the 
rectum (Buettner at al., Phys. Med. Biol. 2009). IGRT daily 
images can be used to re-compute rectum doses for each 
treatment fraction whilst accounting for intra-fraction 
variations in rectum position. As a part of the VoxTox study 
we are analyzing re-computed doses and toxicity in over 1000 
patients treated with image-guided intensity-modulated 
radiotherapy (IG-IMRT) using TomoTherapy. The length of the 
IG scan is kept short for clinical care. We examined whether 
it was sufficient for this research. 
Materials and Methods: We include both retrospective and 
prospective cohorts of prostate cancer patients and acquire 
acute and late toxicity data with a follow-up of 5 years. The 
retrospective cohort was imaged using the standard (STD) 
protocol that is designed to minimize the imaged area whilst 
still enabling soft tissue matching to the prostate. For the 
prospective cohort, we have created a dedicated imaging 
protocol to extend the scan to cover the entire PTV inclusive 
of nodal regions and seminal vesicles. We have demonstrated 
that increases in imaging dose and scan times are negligibly 
small (Bates et. al., Br J Radiol. 2013). This work compares 
the differences in imaging data acquired using STD and 
VoxTox imaging protocols. One oncologist outlined the 
rectum on the planning CT and 37 daily megavoltage CT 
images of patients treated to 74 Gy in 37 fractions. The 
rectum contours on daily images were adjusted to include 
positional corrections applied by treatment radiographers 
prior to RT delivery. A median dose to the rectal surface was 
calculated for all slices in the planning and daily CT images.  
Results: The results from retrospective and from prospective 
cohorts are presented in Figure 1. 
 
 
 
Images acquired using the STD protocol truncate the rectum 
that lies superior of the prostate. In the majority of STD MV 
scans, large parts of rectum receiving doses of 60 Gy and 
above are omitted. For patients imaged according to the 
VoxTox protocol, sufficient coverage of the rectum is 
achieved to account for daily variations in prostate position 
and to enclose all areas of rectum that receive median doses 
of 50 Gy or higher. 
Conclusions: A imaging protocol tailored for research is 
essential to design a prospective study that focuses on rectal 
toxicity. The imaged area in daily scans can be expanded 
with negligible increase in imaging dose and scan time, and 
helps to compensate for daily organ motion. The enhanced 
scans contain all clinically significant data and are useful in 
understanding of dose-toxicity links. Median dose per slice 
evaluation will be useful as a quality assessment tool for 
stratification and analysis of re-calculated daily doses. 
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